Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Nicolaas Schaap(Radboud University Nijmegen), Alessandro M. Vannucchi(University of Florence), Jean‐Jacques Kiladjian(Assistance Publique – Hôpitaux de Paris), Ramón V. Tiu(Cleveland Clinic), Pierre Zachée(Ziekenhuisnetwerk Antwerpen Stuivenberg), Éric Jourdan(Institut de Cancérologie de Bourgogne), Elliott F. Winton(Emory University), Richard T. Silver(Cornell University), Harry C. Schouten(Maastricht University Medical Centre), Francesco Passamonti(University of Insubria), Sonja Zweegman(Amsterdam UMC Location VUmc), Moshe Talpaz(University of Michigan–Ann Arbor), Joanne Lager(Sanofi (United States)), Zhenming Shun(Sanofi (United States)), Ruben A. Mesa(Mayo Clinic in Arizona)
Cited by 326Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis